Illumina Wins Injunction, Loses Triple Damages In BGI IP Case
Illumina can permanently bar its Chinese rival BGI Genomics from further infringing soon-to-expire patents behind its next-generation genome-sequencing technology, but can't triple its $8 million in damages awarded by a jury...To view the full article, register now.
Already a subscriber? Click here to view full article